Trials / Recruiting
RecruitingNCT06911827
A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
A Phase Ib/II Open-Label, Dose-Escalation and Dose-expansion Clinical Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 149 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of QLP2117 in combination with QL2107 in Advanced Solid Tumor Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLP2117 | Specified dose on specified days |
| DRUG | QL2107 | Specified dose on specified days |
Timeline
- Start date
- 2025-05-09
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
- First posted
- 2025-04-04
- Last updated
- 2026-04-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06911827. Inclusion in this directory is not an endorsement.